Jul 16 2026 Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a Antibody Jan 12 2026 Mirador Accelerates Multi-Asset Clinical Pipeline in Immuno-Fibrotic Disease; Closes $250 Million Series B with Premier Investors Sep 27 2024 Endpoints News Names Mirador Therapeutics a 2024 “Endpoints 11” Winner Mar 21 2024 Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases